Dain Hård Nevonen is ranked as Notable practitioner at IFLR 1000 2019
Dain Hård Nevonen is ranked as ”Really excellent and a rising star” at IFLR1000 2014
Vinge has advised Acrinova, an entrepreneurial real estate company operating in the south of Sweden…
Vinge advises Calliditas Therapeutics, a specialty pharmaceutical company listed on Nasdaq Stockholm…
Vinge is advising Vimian and the principal shareholder Fidelio in connection with a private placemen…
Vinge has advised Sdiptech AB (publ) in connection with its list change from Nasdaq First North Prem…
The company description was published on 3 June 2021 and the trading on Nasdaq First North Premier b…
Vinge has advised ABG Sundal Collier and Carnegie in connection with Permascand’s listing on Nasdaq…
The share issue was directed to a number of Swedish and international institutional investors on the…
Corem Property Group AB (publ) has announced a public offer to the shareholders of Klövern AB (publ)…
The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncop…
Vinge has advised EQT in connection with the signing of a combination with Exeter Property Group, a…
Vinge is advising Medivir AB (publ) in connection with a rights issue which will provide Medivir wit…
Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed…
The loan agreement with the EIB grants Oncopeptides access to an unsecured loan facility of up to EU…
Vinge has advised Cell Impact AB (publ) in connection with a directed share issue, whereby Cell Impa…
Vinge advises Calliditas Therapeutics, a specialty pharmaceutical company listed on Nasdaq Stockholm…
The board of directors of Hansa Biopharma has, on the basis of an authorisation granted from the ann…
The board of directors of Medicover has, on the basis of an authorisation granted from the annual ge…
Vinge advises Calliditas Therapeutics in connection with its capital raising and listing on The Nasd…
Vinge has advised Nanoform Finland Plc (“Nanoform”) in connection with its capital raising and listi…
The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncop…
Vinge has advised Equinor ASA in connection with a sale of shares in Lundin Energy AB (publ) through…
Vinge advises Xspray Pharma AB (publ) in connection with its list change from Nasdaq First North Gro…
Vinge has advised the pharmaceutical development company Cinclus Pharma in connection with a capital…
Vinge has advised Industrifonden and Investinor in connection with a sale of in total approximately…
Vinge advises IRLAB Therapeutics in connection with a directed share issue of SEK 70 million and a r…
Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed…
Vinge has advised EQT AB (publ) (“EQT”) in connection with the offering and listing on Nasdaq Stockh…
The Norwegian energy company Equinor ASA announced on 7 July that it had agreed with Lundin Petroleu…
The Board of Directors of Calliditas Therapeutics AB (publ) (“Calliditas”) has resolved on a directe…
The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncop…
Vinge has assisted Nuevolution AB (publ) (“Nuevolution”) in connection with the cash offer to the sh…
The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncop…
The board of directors of Xspray Pharma AB (publ) has resolved on a directed new issue of shares, wh…
Vinge advises Biotage AB (publ) (“Biotage”), listed on Nasdaq Stockholm, in connection with its acqu…
Vinge advised Equinor Technology Ventures AS (”Equinor”) in connection with its acquisition in Medfi…
The board of directors of Hansa Medical has resolved on a directed new issue of shares, whereby Hans…
Klövern AB (publ) has, through its indirectly wholly-owned subsidiary Dagon Sverige AB, made a publi…
In total, 1,2 million shares were placed at a price of SEK 148 per share, corresponding to a total v…
Vinge has advised Autoliv, Inc. (“Autoliv”) and Veoneer, Inc. (“Veoneer”) in connection with the spi…
Vinge advises Calliditas Therapeutics AB (publ) (“Calliditas Therapeutics”) in connection with the l…
Vinge advises Nuevolution AB (publ) in connection with its list change from Nasdaq First North Premi…
Vinge advises ABG Sundal Collier, Skandinaviska Enskilda Banken and Swedbank who are acting as Joint…
The board of directors of Nuevolution has resolved on a directed new issue of shares, whereby Nuevol…
The board of directors of IRLAB Therapeutics has, on the basis of an authorisation granted from the…
The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncop…
The board of directors of Xspray Pharma proposes a directed share issue to be resolved at an extraor…
Vinge has advised Lyko Group AB (publ) (“Lyko”) in connection with its listing on Nasdaq First North…
The board of directors of Hansa Medical has resolved on a directed new issue of ordinary shares, sub…
Vinge assisted EQT V Limited (”EQT”) in connection with the sale of shares in AcadeMedia AB (publ) (…
Vinge advises DGC One AB (publ) (“DGC”) in connection with EQT’s acquisition of 85.2 percent of the…
Vinge advises Medicover AB (publ) (“Medicover”) and its main shareholder Celox Holding AB (“Celox”),…
Advania has, through Advania Holding AB, made a recommended cash offer to the shareholders of Caperi…
The board of directors of Hansa Medical proposes a capital raising through a directed share issue, w…
The outbreak of the coronavirus disease has had a significant impact on people and businesses. The s…
